Arabic Arabic English English French French German German
dark

Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device

Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation (NVAF). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Next Post

Pressure BioSciences Announces Major Business Expansion, Establishing Eco-Friendly Agrochemicals Subsidiary and Initiating Plans to Drive Accretive 2021 Revenue

Related Posts
Total
0
Share